NCT05501522View on ClinicalTrials.gov

Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

840

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

August 22, 2023

Study Completion Date

August 17, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

GBP510 adjuvanted with AS03

injection volume of 0.5mL on Day 0

OTHER

Placebo (Normal Saline)

injection volume of 0.5mL on Day 0

Trial Locations (4)

1008

Policlínico Social Del Norte, Bogotá

44600

Institute of Medicine (IOM), Kathmandu

45200

Dhulikhel, Kathmandu

Unknown

CAIMED (Centro de Atención e Investigación Médica), Chía

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

International Vaccine Institute

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

SK Bioscience Co., Ltd.

INDUSTRY